Adil (Ed) Wakil, M.D. , Scientist; Associate Chief, Division of Hepatology at CPMC, Associate Director of the Kalmanovitz Liver Immunology Laboratory

California Pacific CURRENTS: The online journal of CPMC Research Institute

Prevention and improved treatment of hepatitis B, hepatitis C, and other liver diseases

Research Overview

  • Dr. Wakil studies molecular and genetic changes underlying liver diseases including hepatitis B and C, and he is focused on uncovering new therapeutic targets for the virus.
  • In collaboration with CPMCRI’s Dr. Stewart Cooper [hyperlink], Dr. Wakil investigates how natural killer cells, T cells, and hybrid natural killer T cells interact to clear hepatitis C, and how related sets of genes influence immune response to hepatitis viruses.
  • Validated biomarkers developed by Dr. Wakil and colleagues at CPMC for liver and biliary diseases will be used to personalize treatment and help predict an individual’s response to therapy.

Training

Dr. Wakil received his M.D. from the University of Texas Southwestern in Dallas, Texas, and he was a gastroenterology fellow at the University of California, San Francisco.


 

Publication Search

Publications

Publicover J, Jespersen JM, Johnson AJ, Nishimura SL, Goodsell A, Wakil AE, Rosenthal P, Pai E, Avanesyan L, Cooper S, Baron JL, Liver capsule: Age-influenced hepatic immune priming determines HBV infection fate: Implications from mouse to man. Hepatology

Publicover J, Gaggar A, Nishimura S, Van Horn CM, Goodsell A, Muench MO, Reinhardt RL, van Rooijen N, Wakil AE, Peters M, Cyster JG, Erle DJ, Rosenthal P, Cooper S, Baron JL, Age-dependent hepatic lymphoid organization directs successful immunity to hepatitis B. J Clin Invest

Singh KM, Phung YT, Kohla MS, Lan BY, Chan S, Suen DL, Murad S, Rheault S, Davidson P, Evans J, Singh M, Dohil S, Osorio RW, Wakil AE, Page K, Feng S, Cooper SL, KIR genotypic diversity can track ancestries in heterogeneous populations: a potential confounder for disease association studies. Immunogenetics

Jacobson IM, Brown RS Jr, Freilich B, Afdhal N, Kwo PY, Santoro J, Becker S, Wakil AE, Pound D, Godofsky E, Strauss R, Bernstein D, Flamm S, Pauly MP, Mukhopadhyay P, Griffel LH, Brass CA, WIN-R Study Group., Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology

Carr C, Hollinger FB, Yoffe B, Wakil A, Phillips J, Bzowej N, Leung J, Mirro K, Poordad F, Moore DH, Gish RG, Efficacy of interferon alpha-2b induction therapy before retreatment for chronic hepatitis C. Liver Int

Inductivo-Yu I, Adams A, Gish RG, Wakil A, Bzowej NH, Frederick RT, Bonacini M, Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy. Clin Gastroenterol Hepatol

VIEW ALL
Adil (Ed) Wakil, M.D. , Scientist; Associate Chief, Division of Hepatology at CPMC, Associate Director of the Kalmanovitz Liver Immunology Laboratory
Primary Research Interests
  • Biology and management of hepatitis B and C
  • Immune responses after hepatitis infection
  • Liver transplantation

Hepatology Clinical Trials